[1] Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer, 2019, 19:568.
[2] Finn RS, Ryoo BY, Merle P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol,2019, 20, 37: 4004.
[3] Yau T, Park JW, Finn, RS, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).Ann Oncol,2019,30: 874
[4] Schwacha-Eipper B , Minciuna I, Banz V, et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology, 2020, 72:1488-1490.
[5] Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant, 2019.20:879-883.
[6] DeLeon TT, Salomao MA, Aqel BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The Mayo Clinic experience. J Gastrointest Oncol, 2018,9:1054-1062.
[7] Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunotherapy Cancer,2019, 7:106. 10.
[8] Al Jarroudi O, Ulusakarya A, Almohamad W, et al.Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases.Cureus, 2020, 12:e11150.
[9] Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment- A Case report with systematic literature research. Transplant Direct, 2018, 4:e376.
[10] Hassan NA, Abudayyeh A, Shah M, et al. The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: a systematic review of the literature. J Clin Oncol, 2018, 36:41-41.
[11] Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct, 2018, 4: e376.17.
[12] Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer, 2017, 64:e26682.
[13] Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol, 2019,82:1490-1500.
[14] Kamar N, Lavayssiere L, Muscari F, et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol, 2009, 15: 3426-3430.
[15] Cheikh J El , Massoud R, Abudalle I, et al.Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transpl, 2017, 52:1074-1077.
[16] Tella SH, Mahipal A, Kommalapati A, et al. Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date. Onco Targets Ther, 2019,12:10335-10342.
[17] Amjad W, Kotiah S, Gupta A, et al. Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab.J Clin Exp Hepatol, 2020 10:185-187.
[18] Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.Gut, 2021,70:204-214.
[19] Lee BT, Horwich BH, Chopra S, et al.Checkpoint inhibitor-induced rejection of a liver allograft: A combination of acute T cell-mediated and antibody-mediated rejection. Liver Transpl, 2019,25:1845-1848. |
